TTUHSC School of Medicine Cancer Center
Home School of Medicine Cancer Center

Recent Publications

2009

  1. MH Kang, N Harutyunyan, CP Hall, RA Papa, RB Lock. (2009). In vitro and in vivo Activity of Methotrexate and Aminopterin against acute lymphoblastic leukemia and lymphoma. Br. J. Haematol. 145, 389-393.

2010

  1. Smith MA, Morton CL,: Kolb, EA, Gorlick, R, Keir ST, Carol H, Lock RB, Kang MH, Reynolds CP, MD, Maris JM, Watkins AE, Houghton PJ: Initial testing (Stage 1) of mapatumumab (HGS-ETR1) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 54:307-10, 2010.
  2. Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA: Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Therapeutics 9:101-12, 2010.
  3. Hazen RA, Eder M, Ph.D., Drotar D, Zyzanski S, Reynolds AE, M.F.A, Reynolds CP, Kodish E, Noll RB: A feasibility trial of a video intervention to improve informed consent for parents of children with leukemia Pediatr Blood Cancer 55:113-8, 2010.
  4. Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick N, Raetz E, William Carroll W, Arceci A, Borowitz M, Gaynon P, Gore L, Jeha S, Maurer B, Siegel SE, Biondi A, Kearns P, Narendran A, Silverman L, Smith M, Zwaan M, Whitlock J: Toxicity assessment of new agents incorporated into induction regimens for pediatric acute lymphocytic leukemia (ALL): Results of an international consensus conference. Pediatr Blood Cancer 54:872-878, 2010.
  5. Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH: Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Therapeutics 9:1396-407, 2010.
  6. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ: Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 55:26-34, 2010.
  7. Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu J, Smith MA: Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program. Pediatr Blood Cancer 54:921-6, 2010.
  8. Lee J, Singh H, Maurer BJ, Reynolds CP, Kang MH: A validated LC with fluorescence detection method for simultaneous determination of safingol and D-erythro-sphinganine in human plasma. Chromatographia 71:1087-1091 2010.
  9. Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA: Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer. 55:295-303, 2010.
  10. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program. Pediatr Blood Cancer. 55:668-77,2010.
  11. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger RC, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM: Anti-GD2 antibody with GM-CSF, IL2 and isotretinoin for neuroblastoma: A Children's Oncology Group (COG) Phase III Study. New England J Medicine 363:22-32, 2010.
  12. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada S, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK: Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. New England J Medicine 363:1313-1323, 2010.
  13. Houghton PJ, Morton CL, Kang MH, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA: Evaluation of cytarabine against Ewing sarcoma xenografts by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 55:1224-6, 2010.
  14. Shusterman SS, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MRA, Wagner B, Gan J, Eickhoff J, De Santes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, and Sondel PM: Anti-tumor activity of hu14.18-IL2 (EMD 273063) in relapsed/refractory neuroblastoma patients: a Children's Oncology Group (COG) phase II study. J Clinical Oncology 28:4969-75, 2010.
  15. Cai, W, Maldonado V, Ji L, Sposto R, Reynolds CP, Keshelava N: Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer 103:1369-1379, 2010.
  16. Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA: Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer 55:1126-33, 2010.
  17. Hadjidaniel MD and Reynolds CP: Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by retinoic acid is mediated by the anti-apoptotic Bcl-2 family proteins. Mol Cancer Therapeutics 9:3164-74, 2010.
  18. Kapranov P, St. Laurent G, Raz T, Fatih Ozsolak F, Reynolds CP, Sorensen PHB, Reaman G, Milos P, Arceci RJ, Thompson JF, Triche TJ: The majority of total nuclear-encoded non-ribosomal RNA in a human cell is "dark matter" unannotated RNA BMC Biology 8:149 [Epub] 2010
  19. Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB: Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 55:1329-37, 2010.
  20. Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA: Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program Pediatr Blood Cancer. 2010 Dec 27. [Epub]

2011

  1. JP Cooper, S Bang, H Singh, SC Williams, MH Kang. (2011) Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia. Pediatric Blood Cancer. (in press).
  2. C Zhang, YK Ryu, TZ Chen, CP Hall, DR Webster, MH Kang. (2011) Synergistic Activity of Rapamycin and Dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. Leukemia Res. (in press).
  3. Kang MH, Smith MA, Morton CL, Nino Keshelava N, Houghton PJ, Reynolds CP: National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 56:239-49, 2011.
  4. Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer 58:191-9, 2011
  5. Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ: Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer. 56:595-603, 2010
  6. Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ: Initial Testing (Stage 1) of the polyamine analog PG11047 by the Pediatric Preclinical Testing Program Pediatr Blood Cancer 57:268-74, 2011.
  7. Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, MS, Smith MA, MD, Houghton PJ: Initial testing of lenalidomide by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 57:606-11, 2011.
  8. Cooper J, Kyunghwa H, Hardeep S, Wang, D, Reynolds CP, Robert C, Simon W, Maurer BJ, Kang MH: Fenretinide metabolism in humans and mice: Utilizing pharmacologic modulation of its metabolic pathway to increase systemic exposure. British J Pharmacology 163:1263-75, 2011.
  9. Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB: Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol. 68:1291-304, 2011
  10. Kummar S, Gutierrez ME, Maurer BJ, Reynolds CP, Kang M, Singh H, Crandon S, Murgo AJ, Doroshow JH: Phase I trial of fenretinide Lym-X-sorb oral powder in adults with solid tumors and lymphomas. Anticancer Res. 31:961-6, 2011.
  11. Fang H, Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP: Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clinical Cancer Research 17:7093-104, 2011.
  12. Villablanca JG, London WB, Naranjo A, McGrady MS, Ames MM, Joel M. Reid JM, McGovern RM, Buhrow SA, Stranzinger JH, Kitchen BJ, Sondel PM, Parisi M, Shulkin B, Yanik GA, Cohn S, Reynolds CP: Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the Children's Oncology Group NSC #374551; IND# 40294. Clinical Cancer Research 17:6858-6866, 2011.

2012

  1. Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA: Initial testing (stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:185-8, 2012
  2. Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MA: Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer. 58:200-9, 2012
  3. Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer. 58:916-23, 2012
  4. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA: Initial testing (Stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatr Blood Cancer. 58:636-9, 2012
  5. Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ: Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer. 59: 329-32, 2012
  6. Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA: Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:518-24, 2012. PMID: 22102563
  7. Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA: Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:749-52, 2012. PMID: 22052829
  8. Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA: Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer. 58:815-8, 2012. PMID 22052798
  9. Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ: Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:246-53, 2012. PMID: 22012946
  10. Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel J, Reynolds CP: Novel cell lines accurately reflect pediatric brain tumors. J Neurooncology 107:269-80, 2012. PMID: 22120608
  11. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:1266-74, 2012. PMID: 22315240
  12. Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJ: Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. Pediatr Blood Cancer. 59:753-5, 2012. PMID: 22315235
  13. Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, Collins MH, Tagge E, Adkins S, Reynolds CP, Murray K, Lavey RS, Matthay KK, Castleberry R, Maris JM, Cohn SL: Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: Results of Children's Oncology Group study P9641. J Clin Oncol. 30:1842-8, 2012. PMID: 22529259
  14. Szymanska B, Wilczynska-Kalak U, Kang MH, Liem NL, Carol H, Boehm I, Groepper D, Reynolds CP, Stewart CF, Lock RB: Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One. 7:e33894, 2012. PMID: 22479469
  15. Goldsmith KC, Gross M, Peirce S, Luyindula D, Liu X, Vu A, Sliozberg M, Guo R, Zhao H, Reynolds CP, Hogarty MD: Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res. 72:2565-2577, 2012.
  16. Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB: Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:633-41, 2012. PMID: 22753001

2013

  1. Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MA: Initial testing (stage 1) of the phosphatidylinositol 3' kinase Inhibitor, SAR245408 (XL147) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 60:791-798, 2013.
  2. Shibina A, Seidel D, Somanchi S, Lode HN, Lee DA, Reynolds CP, Huebener N: Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. J Mol Med 91:459-472, 2013.
  3. Sausen M, Leary RJ, Wu J, Reynolds CP, Liu X, Maris J, Blackford A, Parmigiani G, Diaz LA, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE, Hogarty MD: Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genetics 45:12-17, 2013.
  4. Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA: Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:783-90, 2013. PMID: 23335050
  5. Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:1860-7, 2013. PMID: 23798344
  6. Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. : Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:E42-5, 2013. PMID: 23303741
  7. Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA: Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 60:1325-32, 2013. PMID 23553917
  8. Maurer BJ, Kang MH, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Villablanca JG, Czarnecki S, Beth Hasenauer B, Reynolds CP, Marachelian A: Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed neuroblastoma: A report from the NANT consortium. Pediatr Blood Cancer 60:1801-8, 2013. PMID: 23813912
  9. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, M.D., LaQuaglia MP, Yu AL, M.D., Diller L, Buxton A, Park JP, Cohn SL, Maris JM, Reynolds CP, Villablanca JG: Purged versus non-purged peripheral blood stem cell transplant for neuroblastoma. Lancet Oncology 14:999-1008, 2013. PMID: 23890779
  10. Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MA: Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Oct 26. doi: 10.1002/pbc.24800. [Epub ahead of print] PMID: 24166988
  11. Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R: Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2013 Sep 4. doi: 10.1002/pbc.24724. [Epub ahead of print] PMID: 24038993
  12. May, W.A., Grigoryan, R.S., Keshelava, N., Cabral, D.J., Christensen, L.L., Jenabi, J., Ji, L., Triche, T.J., Lawlor, E.R., Reynolds, C.P. (2013). Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One 8, e80060. PM:24312454

2014

  1. Alfano, R., Youngblood, B.A., Zhang, D., Huang, N., MacDonald, C.C.(2014). Human leukemia inhibitory factor produced by the ExpressTec method from rice (Oryza sativa L.) is active in human neural stem cells and mouse induced pluripotent stem cells. Bioengineered 5, 180-5.
  2. Bright, R.K., Bright, J.D., Byrne, J.A. (2014). Overexpressed oncogenictumor-self antigens. Hum Vaccin Immunother 10, 3297-305.
  3. Byrne, J.A., Frost, S., Chen, Y., Bright, R.K. (2014). Tumor protein D52(TPD52) and cancer-oncogene understudy or understudied oncogene? Tumour Biol 35, 7369-82.
  4. Carol, H., Maris, J.M., Kang, M.H., Reynolds, C.P., Kolb, E.A., Gorlick, R., Keir, S.T., Wu, J., Kurmasheva, R.T., Houghton, P.J., Smith, M.A., Lock, R.B., Lyalin, D. (2014). Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer 61, 1493-6. PM:24664981
  5. Carol, H., Gorlick, R., Kolb, E.A., Morton, C.L., Manesh, D.M., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Wozniak, A., Hickson, I., Lyalin, D., Kurmasheva, R.T., Houghton, P.J., Smith, M.A., Lock, R. (2014). Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61, 245-52. PM:24038993
  6. Farooqi, A.S., Dagg, R.A., Choi, L.M., Shay, J.W., Reynolds, C.P., Lau,L.M. (2014). Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. J Neurooncol 119, 17-26. PM:24792489
  7. Fiori, M.C., Reuss, L., Cuello, L.G., Altenberg, G.A. (2014). Functional analysis and regulation of purified connexin hemichannels. Front Physiol 5:71. doi: 10.3389/fphys.2014.00071. eCollection; 2014.,71.
  8. Gorlick, R., Kolb, E.A., Keir, S.T., Maris, J.M., Reynolds, C.P., Kang, M.H.,Carol, H., Lock, R., Billups, C.A., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2014). Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61, 158-64. PM:23956067
  9. Grozdanov, P.N., MacDonald, C.C. (2014). High-throughput sequencing of RNA isolated by cross-linking and immunoprecipitation (HITS-CLIP) to determine sites of binding of CstF-64 on nascent RNAs. Methods Mol Biol 1125:187-208. doi: 10.1007/978-1-62703-971-0_ 17., 187-208.
  10. Hockert, J.A., MacDonald, C.C. (2014). The stem-loop luciferase assay for polyadenylation (SLAP) method for determining CstF-64-dependentpolyadenylation activity. Methods Mol Biol 1125:109-17. doi: 10.1007978-1-62703-971-0_ 9., 109-17.
  11. Houghton, P.J., Kurmasheva, R.T., Lyalin, D., Maris, J.M., Kolb, E.A.,Gorlick, R., Reynolds, C.P., Kang, M.H., Keir, S.T., Wu, J., Smith, M.A. (2014). Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatr Blood Cancer 61, 1972-9. PM:25131802
  12. Kang, M.H., Villablanca, J.G., Glade Bender, J.L., Matthay, K.K., Groshen,S., Sposto, R., Czarnecki, S., Ames, M.M., Reynolds, C.P., Marachelian,A., Maurer, B.J. (2014). Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Res Notes 7, 256. PM:247554753
  13. Kang, M.H., Reynolds, C.P., Maris, J.M., Gorlick, R., Kolb, E.A., Lock, R.,Carol, H., Keir, S.T., Wu, J., Lyalin, D., Kurmasheva, R.T., Houghton, P.J.,Smith, M.A. (2014). Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer 61, 1486-9. PM:24623675
  14. Kurmasheva, R.T., Reynolds, C.P., Kang, M.H., Allievi, C., Houghton, P.J.,Smith, M.A. (2014). Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatr Blood Cancer 61, 922-4. PM:24166988
  15. Lairson, D.R., Chang, Y.C., Byrd, T.L., Lee, S.J., Fernandez, M.E., Wilson,K.M. (2014). Cervical cancer screening with AMIGAS: a cost-effectiveness analysis. Am J Prev Med 46, 617-23.
  16. Leon-Paravic, C.G., Figueroa, V.A., Guzman, D.J., Valderrama, C.F., Vallejos, A.A., Fiori, M.C., Altenberg, G.A., Reuss, L., Retamal, M.A.(2014). Carbon monoxide (CO) is a novel inhibitor of connexin hemichannels. J Biol Chem 289, 36150-7.
  17. Nelius, T., Martinez-Marin, D., Hirsch, J., Miller, B., Rinard, K., Lopez, J.,de, R.W., Filleur, S. (2014). Pigment epithelium-derived factorexpression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer. Cell Death Dis 5,e1210. PM:24810046
  18. Roslan, N., Bieche, I., Bright, R.K., Lidereau, R., Chen, Y., Byrne, J.A. (2014). TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Mol Carcinog 53, 807-19.
  19. Ryu, Y., Hall, C.P., Reynolds, C.P., Kang, M.H. (2014). Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia celllines. Exp Biol Med (Maywood) 239, 1390-402. PM:24951472
  20. Sennoune, S.R., Bermudez, L.E., Lees, J.C., Hirsch, J., Filleur, S.,Martinez-Zaguilan, R. (2014). Vacuolar H+-ATPase is down-regulatedby the angiogenesis-inhibitory pigment epithelium-derived factor inmetastatic prostate cancer cells. Cell Mol Biol (Noisy-le-grand) 60,45-52. PM:24857383
  21. Shah, E.D., Fisch, B.M., Arceci, R.J., Buckley, J.D., Reaman, G.H.,Sorensen, P.H., Triche, T.J., Reynolds, C.P. (2014). DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development. Cancer Chemother Pharmacol 73, 1089-93.PM:24663501
  22. Sonawane, P., Cho, H.E., Tagde, A., Verlekar, D., Yu, A.L., Reynolds,C.P., Kang, M.H. (2014). Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acidmetabolite 4-oxo-13-cis-retinoic acid in neuroblastoma. Br J Pharmacol171, 5330-44. PM:25039756
  23. Swartz, D.J., Mok, L., Botta, S.K., Singh, A., Altenberg, G.A., Urbatsch, I.L. (2014). Directed evolution of P-glycoprotein cysteines reveals site-specific, non-conservative substitutions that preserve multidrug resistance. Biosci Rep 34, e00116.
  24. Tagde, A., Singh, H., Kang, M.H., Reynolds, C.P. (2014) . The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Blood Cancer J 4, e229. PM:25036800
  25. Volk, R.J., McFall, S.L., Cantor, S.B., Byrd, T.L., Le, Y.C., Kuban, D.A.,Mullen, P.D. (2014) . 'It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer. Psychooncology 23, 467-72.
  26. Youngblood, B.A., MacDonald, C.C. (2014) . CstF-64 is necessary for endoderm differentiation resulting in cardiomyocyte defects. Stem Cell Res 13, 413-21.
  27. Youngblood, B.A., Grozdanov, P.N., MacDonald, C.C. (2014) . CstF-64 supports pluripotency and regulates cell cycle progression in embryonic stem cells through histone 3' end processing. Nucleic Acids Res 42,8330-42.
  28. .Youngblood, B.A., Alfano, R., Pettit, S.C., Zhang, D., Dallmann, H.G., Huang, N., MacDonald, C.C. (2014) . Application of recombinant human leukemia inhibitory factor (LIF) produced in rice (Oryza sativa L.) for maintenance of mouse embryonic stem cells. J Biotechnol 20;172:67-72.doi: 10.1016/j.jbiotec.2013.12.012. Epub; 2013 Dec 29., 67-72.
  29. Zoghbi, M.E., Altenberg, G.A. (2014). ATP binding to two sites is necessary for dimerization of nucleotide-binding domains of ABC proteins. Biochem Biophys Res Commun 443, 97-102.

2015

  1. Anderson, C.P., Matthay, K.K., Perentesis, J.P., Neglia, J.P., Bailey, H.H.,Villablanca, J.G., Groshen, S., Hasenauer, B., Maris, J.M., Seeger, R.C.,Reynolds, C.P. (2015). Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer 62, 1739-46. PM:26153194
  2. Babu, E., Bhutia, Y.D., Ramachandran, S., Gnanaprakasam, J.P., Prasad,P.D., Thangaraju, M., Ganapathy, V. (2015). Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer. Biochem J 469, 17-23.
  3. Bhutia, Y.D., Ganapathy, V. (2015). Short, but Smart: SCFAs Train TCells in the Gut to Fight Autoimmunity in the Brain. Immunity 20;43,629-31.
  4. Bhutia, Y.D., Babu, E., Ramachandran, S., Ganapathy, V. (2015). Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. Cancer Res 75, 1782-8.
  5. Bhutia, Y.D., Babu, E., Ganapathy, V. (2015). Interferon-gamma induces a tryptophan-selective amino acid transporter in human colonicepithelial cells and mouse dendritic cells. Biochim Biophys Acta 1848,453-62.
  6. Fernandez, M.E., Savas, L.S., Wilson, K.M., Byrd, T.L., Atkinson, J.,Torres-Vigil, I., Vernon, S.W. (2015). Colorectal cancer screening among Latinos in three communities on the Texas-Mexico border. Health Educ Behav 42, 16-25.
  7. Fiori, M.C., Krishnan, S., Cortes, D.M., Retamal, M.A., Reuss, L.,Altenberg, G.A., Cuello, L.G. (2015). Functional hemichannels formed by human connexin 26 expressed in bacteria. Biosci Rep 35, e00177.
  8. Gopal, E., Babu, E., Ramachandran, S., Bhutia, Y.D., Prasad, P.D.,Ganapathy, V. (2015). Species-specific influence of lithium on the activity of SLC13A5 (NaCT) : lithium-induced activation is specific for the transporter in primates. J Pharmacol Exp Ther 353, 17-26.
  9. Grozdanov, P.N., MacDonald, C.C. (2015). Generation of plasmid vectors expressing FLAG-tagged proteins under the regulation of humanelongation factor-1alpha promoter using Gibson assembly. J Vis Exp , 10.
  10. Gurav, A., Sivaprakasam, S., Bhutia, Y.D., Boettger, T., Singh, N.,Ganapathy, V. (2015). Slc5a8, a Na+-coupled high-affinity transporter for short-chain fatty acids, is a conditional tumour suppressor in colon thatprotects against colitis and colon cancer under low-fibre dietary conditions. Biochem J 469, 267-78.
  11. Kamili, A., Roslan, N., Frost, S., Cantrill, L.C., Wang, D., Della-Franca, A., Bright, R.K., Groblewski, G.E., Straub, B.K., Hoy, A.J., Chen, Y., Byrne,J.A. (2015). TPD52 expression increases neutral lipid storage within cultured cells. J Cell Sci 128, 3223-38.
  12. Kang, M.H., Wang, J., Makena, M.R., Lee, J.S., Paz, N., Hall, C.P., Song, M.M., Calderon, R.I., Cruz, R.E., Hindle, A., Ko, W., Fitzgerald, J.B.,Drummond, D.C., Triche, T.J., Reynolds, C.P. (2015) . Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumorxenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res 21, 1139-50. PM:25733708
  13. Kolb, E.A., Gorlick, R., Keir, S.T., Maris, J.M., Kang, M.H., Reynolds, C.P.,Lock, R.B., Carol, H., Wu, J., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2015). Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 62, 1106-9. PM:25407467
  14. Manna, P.R., Stetson, C.L., Daugherty, C., Shimizu, I., Syapin, P.J., Garrel, G., Cohen-Tannoudji, J., Huhtaniemi, I., Slominski, A.T., Pruitt, K., Stocco, D.M. (2015). Up-regulation of steroid biosynthesis by retinoid signaling: Implications for aging. Mech Ageing Dev 150:74-82. doi: 10.1016j.mad.2015.08.007. Epub; 2015 Aug 21., 74-82.
  15. Manna, P.R., Sennoune, S.R., Martinez-Zaguilan, R., Slominski, A.T.,Pruitt, K. (2015). Regulation of retinoid mediated cholesterol efflux involves liver X receptor activation in mouse macrophages. Biochem Biophys Res Commun 464, 312-7.
  16. McFall, S.L., Mullen, P.D., Byrd, T.L., Cantor, S.B., Le, Y.C., Torres-Vigil, I., Pettaway, C., Volk, R.J. (2015). Treatment decisions for localized prostate cancer: a concept mapping approach. Health Expect 18, 2079-90.
  17. Pandey, S., Simmons, G.E., Jr., Malyarchuk, S., Calhoun, T.N., Pruitt, K. (2015). A novel MeCP2 acetylation site regulates interaction with ATRX and HDAC1. Genes Cancer 6, 408-21.
  18. Reynolds, C.P., Kang, M.H., Maris, J.M., Kolb, E.A., Gorlick, R., Wu, J.,Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2015). Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatr Blood Cancer 62,1897-905. PM:26154614
  19. Roncancio, A.M., Ward, K.K., Sanchez, I.A., Cano, M.A., Byrd, T.L.,Vernon, S.W., Fernandez-Esquer, M.E., Fernandez, M.E. (2015). Using the Theory of Planned Behavior to Understand Cervical Cancer Screening Among Latinas. Health Educ Behav 42, 621-6.
  20. .Seidel, D., Shibina, A., Siebert, N., Wels, W.S., Reynolds, C.P., Huebener,N., Lode, H.N. (2015). Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Cancer Immunol Immunother 64, 621-34. PM:25711293
  21. Sheard, M.A., Ghent, M.V., Cabral, D.J., Lee, J.C., Khankaldyyan, V., Ji,L., Wu, S.Q., Kang, M.H., Sposto, R., Asgharzadeh, S., Reynolds, C.P. (2015). Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration. Exp Cell Res 334, 78-89. PM:25845499
  22. Simmons, G.E., Jr., Pruitt, W.M., Pruitt, K. (2015). Diverse roles of SIRT1 in cancer biology and lipid metabolism. Int J Mol Sci 16, 950-65.
  23. Smith, M.A., Reynolds, C.P., Kang, M.H., Kolb, E.A., Gorlick, R., Carol, H.,Lock, R.B., Keir, S.T., Maris, J.M., Billups, C.A., Lyalin, D., Kurmasheva,R.T., Houghton, P.J. (2015). Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 21, 819-32.PM:25500058
  24. Smith, M.A., Hampton, O.A., Reynolds, C.P., Kang, M.H., Maris, J.M.,Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Keir, S.T., Wu, J., Kurmasheva, R.T., Wheeler, D.A., Houghton, P.J. (2015). Initial testing (stage 1) ofthe PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 62, 91-8. PM:25263539

2016

  1. Arjunan, P., Gnanaprakasam, J.P., Ananth, S., Romej, M.A., Rajalakshmi,V.K., Prasad, P.D., Martin, P.M., Gurusamy, M., Thangaraju, M., Bhutia,Y.D., Ganapathy, V. (2016) . Increased Retinal Expression of the Pro-Angiogenic Receptor GPR91 via BMP6 in a Mouse Model of Juvenile Hemochromatosis. Invest Ophthalmol Vis Sci 57, 1612-9.
  2. Attiyeh, E.F., Maris, J.M., Lock, R., Reynolds, C.P., Kang, M.H., Carol, H.,Gorlick, R., Kolb, E.A., Keir, S.T., Wu, J., Landesman, Y., Shacham, S.,Lyalin, D., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2016). Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330) : A report from the pediatric preclinical testing program. Pediatr Blood Cancer 63, 276-86. PM:26398108
  3. Bhutia, Y.D., Babu, E., Ganapathy, V. (2016). Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine. Biochem J473, 1503-6.
  4. Bhutia, Y.D., Babu, E., Ramachandran, S., Yang, S., Thangaraju, M., Ganapathy, V. (2016). SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. Biochem J 473,1113-24.
  5. Bhutia, Y.D., Ganapathy, V. (2016) . Glutamine transporters inmammalian cells and their functions in physiology and cancer. Biochim Biophys Acta 1863, 2531-9.
  6. Chen, N.E., Maldonado, N.V., Khankaldyyan, V., Shimada, H., Song, M.M.,Maurer, B.J., Reynolds, C.P. (2016) . Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with theMicrotubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts. Mol Cancer Ther 15, 2653-64. PM:27530131
  7. Dalamon, V., Fiori, M.C., Figueroa, V.A., Oliva, C.A., Del, R.R., Gonzalez,W., Canan, J., Elgoyhen, A.B., Altenberg, G.A., Retamal, M.A. (2016). Gap-junctional channel and hemichannel activity of two recently identified connexin 26 mutants associated with deafness. Pflugers Arch 468, 909-18.
  8. Dykes, S.S., Gray, A.L., Coleman, D.T., Saxena, M., Stephens, C.A.,Carroll, J.L., Pruitt, K., Cardelli, J.A. (2016). The Arf-like GTPase Arl8bis essential for three-dimensional invasive growth of prostate cancer in vitroand xenograft formation and growth in vivo. Oncotarget 7, 31037-52.
  9. Gorlick, R., Kolb, E.A., Keir, S.T., Maris, J.M., Lock, R.B., Carol, H., Reynolds, C.P., Kang, M.H., Billups, C.A., Collins, J., Kurmashev, D., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2016). Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models bythe Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63,443-50. PM:26797892
  10. Grozdanov, P.N., Amatullah, A., Graber, J.H., MacDonald, C.C. (2016) .TauCstF-64 Mediates Correct mRNA Polyadenylation and Splicing of Activator and Repressor Isoforms of the Cyclic AMP-Responsive ElementModulator (CREM) in Mouse Testis. Biol Reprod 94, 34.
  11. Hall, C.P., Reynolds, C.P., Kang, M.H. (2016). Modulation ofGlucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Clin Cancer Res 22, 621-32. PM:26080839
  12. Harris, J.C., Martinez, J.M., Grozdanov, P.N., Bergeson, S.E., Grammas, P., MacDonald, C.C. (2016) . The Cstf2t Polyadenylation Gene Plays a Sex-Specific Role in Learning Behaviors in Mice. PLoS One 11, e0165976.
  13. Irving, B.A., Wood, G.C., Bennotti, P.N., Babu, E., Deshpande, A., Lent,M.R., Petrick, A., Gabrielsen, J., Strodel, W., Gerhard, G.S., Still, C.D., Ganapathy, V., Rolston, D.D. (2016) . Nutrient Transporter Expression in the Jejunum in Relation to Body Mass Index in Patients Undergoing Bariatric Surgery. Nutrients 8, E683.
  14. Kang, M.H., Reynolds, C.P., Kolb, E.A., Gorlick, R., Carol, H., Lock, R.,Keir, S.T., Maris, J.M., Wu, J., Lyalin, D., Kurmasheva, R.T., Houghton,P.J., Smith, M.A. (2016) . Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63, 1744-52. PM:27238606
  15. Krishnan, S., Fiori, M.C., Whisenant, T.E., Cortes, D.M., Altenberg, G.A., Cuello, L.G. (2016). An Escherichia coli-Based Assay to Assess the Function of Recombinant Human Hemichannels. J Biomol Screen ,1087057116675321.
  16. Krytska, K., Ryles, H.T., Sano, R., Raman, P., Infarinato, N.R., Hansel,T.D., Makena, M.R., Song, M.M., Reynolds, C.P., Mosse, Y.P. (2016). Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma. Clin Cancer Res 22, 948-60. PM:26438783
  17. Le, Y.L., McFall, S.L., Byrd, T.L., Volk, R.J., Cantor, S.B., Kuban, D.A., Mullen, P.D. (2016). Is "Active Surveillance" an Acceptable Alternative?: A Qualitative Study of Couples' Decision Making about Early-Stage,Localized Prostate Cancer. Narrat Inq Bioeth 6, 51-61.
  18. Lock, R., Carol, H., Maris, J.M., Kolb, E.A., Gorlick, R., Reynolds, C.P.,Kang, M.H., Keir, S.T., Wu, J., Purmal, A., Gudkov, A., Kurmashev, D.,Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2016). Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer, PM:27650817
  19. Luo, Q., Gong, P., Sun, M., Kou, L., Ganapathy, V., Jing, Y., He, Z., Sun,J. (2016). Transporter occluded-state conformation-inducedendocytosis: Amino acid transporter ATB0,+-mediated tumor targeting of liposomes for docetaxel delivery for hepatocarcinoma therapy. J Control Release 243:370-380. doi: 10.1016/j.jconrel.2016.10.031. Epub; 2016 Nov 1., 370-80.
  20. Manna, P.R., Stetson, C.L., Slominski, A.T., Pruitt, K. (2016). Role of the steroidogenic acute regulatory protein in health and disease. Endocrine 51, 7-21.
  21. Murphy, B., Yin, H., Maris, J.M., Kolb, E.A., Gorlick, R., Reynolds, C.P.,Kang, M.H., Keir, S.T., Kurmasheva, R.T., Dvorchik, I., Wu, J., Billups,C.A., Boateng, N., Smith, M.A., Lock, R.B., Houghton, P.J. (2016). Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Res 76, 5798-809. PM:27496711
  22. Pathania, R., Ramachandran, S., Mariappan, G., Thakur, P., Shi, H., Choi,J.H., Manicassamy, S., Kolhe, R., Prasad, P.D., Sharma, S., Lokeshwar, B.L., Ganapathy, V., Thangaraju, M. (2016). Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth. Cancer Res 76, 3224-35.
  23. Promsote, W., Powell, F.L., Veean, S., Thounaojam, M., Markand, S.,Saul, A., Gutsaeva, D., Bartoli, M., Smith, S.B., Ganapathy, V., Martin,P.M. (2016). Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease. Antioxid Redox Signal 25, 921-35.
  24. Pruitt, K. (2016). Molecular and Cellular Changes During CancerProgression Resulting From Genetic and Epigenetic Alterations. Prog Mol Biol Transl Sci 144:3-47. doi: 10.1016/bs.pmbts.2016.09.001. Epub; 2016 Oct 7., 3-47.
  25. Shanmugam, A.K., Mysona, B.A., Wang, J., Zhao, J., Tawfik, A., Sanders,A., Markand, S., Zorrilla, E., Ganapathy, V., Bollinger, K.E., Smith, S.B.(2016). Progesterone Receptor Membrane Component 1 (PGRMC1) Expression in Murine Retina. Curr Eye Res 41, 1105-12.
  26. Sivaprakasam, S., Gurav, A., Paschall, A.V., Coe, G.L., Chaudhary, K.,Cai, Y., Kolhe, R., Martin, P., Browning, D., Huang, L., Shi, H., Sifuentes,H., Vijay-Kumar, M., Thompson, S.A., Munn, D.H., Mellor, A., McGaha,T.L., Shiao, P., Cutler, C.W., Liu, K., Ganapathy, V., Li, H., Singh, N. (2016). An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression ofintestinal carcinogenesis. Oncogenesis 5, e238.
  27. Thompson, B., Carosso, E.A., Jhingan, E., Wang, L., Holte, S.E., Byrd,T.L., Benavides, M.C., Lopez, C., Martinez-Gutierrez, J., Ibarra, G., Gonzalez, V.J., Gonzalez, N.E., Duggan, C.R. (2016). Results of arandomized controlled trial to increase cervical cancer screening among rural Latinas. Cancer , 10.
  28. Thu, K.L., Papari-Zareei, M., Stastny, V., Song, K., Peyton, M., Martinez,V.D., Zhang, Y.A., Castro, I.B., Varella-Garcia, M., Liang, H., Xing, C.,Kittler, R., Milchgrub, S., Castrillon, D.H., Davidson, H.L., Reynolds, C.P.,Lam, W.L., Lea, J., Gazdar, A.F. (2016) . A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget, PM:27302921
  29. Villablanca, J.G., Volchenboum, S.L., Cho, H., Kang, M.H., Cohn, S.L., Anderson, C.P., Marachelian, A., Groshen, S., Tsao-Wei, D., Matthay, K.K., Maris, J.M., Hasenauer, C.E., Czarnecki, S., Lai, H., Goodarzian, F.,Shimada, H., Reynolds, C.P. (2016) . A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer 63, 1349-56. PM:27092812
  30. Zoghbi, M.E., Cooper, R.S., Altenberg, G.A. (2016) . The Lipid Bilayer Modulates the Structure and Function of an ATP-binding Cassette Exporter. J Biol Chem 291, 4453-61.

2017

  1. Cho, H.E., Min, H.K. (2017). Analysis of fenretinide and its metabolitesin human plasma by liquid chromatography-tandem mass spectrometryand its application to clinical pharmacokinetics. J Pharm Biomed Anal 132,117-24. PM:27701038
  2. Cooper, J.P., Reynolds, C.P., Cho, H., Kang, M.H. (2017). Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives. Exp Biol Med (Maywood) 242, 1178-84. PM:28429653
  3. Coothankandaswamy, V., Cao, S., Xu, Y., Prasad, P.D., Singh, P.K.,Reynolds, C.P., Yang, S., Ogura, J., Ganapathy, V., Bhutia, Y.D. (2016). Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Br J Pharmacol, PM:27747870
  4. Dagg, R.A., Pickett, H.A., Neumann, A.A., Napier, C.E., Henson, J.D.,Teber, E.T., Arthur, J.W., Reynolds, C.P., Murray, J., Haber, M., Sobinoff,A.P., Lau, L.M.S., Reddel, R.R. (2017). Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. Cell Rep 19, 2544-56.PM:28636942
  5. Fendley GA, Urbatsch IL, Sutton RB, Zoghbi ME, Altenberg G.A. (2017). Nucleotide dependence of the dimerization of ATP binding cassette nucleotide binding domains. Biochem. Biophys. Res Commun. In Press.
  6. Harenza, J.L., Diamond, M.A., Adams, R.N., Song, M.M., Davidson, H.L.,Hart, L.S., Dent, M.H., Fortina, P., Reynolds, C.P., Maris, J.M. (2017). Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. SciData 4, 170033. PM:28350380
  7. Kurmasheva, R.T., Gorlick, R., Kolb, E.A., Keir, S.T., Maris, J.M., Lock,R.B., Carol, H., Kang, M., Reynolds, C.P., Wu, J., Houghton, P.J., Smith,M.A. (2017). Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64, PM:27786412
  8. Li, W., Zhang, Y., Reynolds, C.P., Pappas, D. ( 2017) . Microfluidic Separation of Lymphoblasts for the Isolation of Acute Lymphoblastic Leukemia Using the Human Transferrin Receptor as a Capture Target. Anal Chem 89, 7340-7. PM:28656755
  9. Lock, R., Carol, H., Maris, J.M., Kolb, E.A., Gorlick, R., Reynolds, C.P.,Kang, M.H., Keir, S.T., Wu, J., Purmal, A., Gudkov, A., Kurmashev, D.,Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2017). Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer 64, PM:27650817
  10. Lopez-Barcons, L., Maurer, B.J., Kang, M.H., Reynolds, C.P. (2017). P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. Int J Cancer 141, 405-13. PM:28340497
  11. Makena, M.R., Koneru, B., Nguyen, T.H., Kang, M.H., Reynolds, C.P. (2017). Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies. Mol Cancer Ther 16, 649-61. PM:28119491
  12. Mohrbacher, A.M., Yang, A.S., Groshen, S., Kummar, S., Gutierrez, M.E., Kang, M.H., Tsao-Wei, D., Reynolds, C.P., Newman, E.M., Maurer, B.J. (2017). Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial. Clin Cancer Res , PM:28420721
  13. Penaranda E, Moloku J, Hernandez I, Salaiz R, Nguyen N, Byrd T.L.,Fernandez M.E. (2017). Attitudes towards self-sampling for HPV infection for cervical cancer screening among primary care attendees on the US-Mexico border. Southern Medical Journal In Press.